Clinical Trials Logo

Alpha1-antitrypsin Deficiency clinical trials

View clinical trials related to Alpha1-antitrypsin Deficiency.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02722304 Terminated - Clinical trials for Chronic Obstructive Pulmonary Disease

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

Start date: November 2, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to conduct a pilot study to evaluate the safety and efficacy of weekly administration of Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy in subjects with A1PI deficiency and emphysema/ chronic obstructive pulmonary disease (COPD).

NCT ID: NCT00313144 Terminated - Clinical trials for Alpha1-antitrypsin Deficiency

Aralast alpha1-proteinase Inhibitor Surveillance Study

Start date: June 9, 2006
Phase: Phase 4
Study type: Interventional

The primary objectives of this Phase 4, open label, prospective U.S. surveillance study are to evaluate the health outcomes of Alpha 1-Antitrypsin (AAT)-deficient subjects who are initiating treatment with ARALAST on patient-related outcomes (PRO), i.e., health-related quality of life (HRQoL), healthcare resource utilization (HCRU), and various laboratory analyses to evaluate the safety of long-term administration of ARALAST. Up to 120 subjects will be enrolled and assessed for HRQoL and HCRU at baseline and every 6-months thereafter, for 2 years. A subset of subjects will be enrolled into the blood draw portion of the study, which will also include assessments of antibodies to ARALAST, and chemistry panel. Subjects will be treated according to the prescribing (attending) physician's instructions based on the prescribing information given in the ARALAST package insert.